Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB‐1- and/or ErbB‐2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. - Ellis,M.J.; Coop,A.; Singh,B.; Mauriac,L.; Llombert-Cussac,A.; Janicke,F. (J Clin Oncol, 2001)